Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.
about
Recent advances in T-cell engineering for use in immunotherapyPrediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing.Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators.Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway.Precision medicine driven by cancer systems biology.T-cell receptor-engineered T cells for cancer treatment: current status and future directions.Immune targets and neoantigens for cancer immunotherapy and precision medicine.Immunoplasticity in cutaneous melanoma: beyond pure morphology.Is immunotherapy here to stay in multiple myeloma?Targeting neoantigens to augment antitumour immunity.Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.Hematopoietic stem cell transplantation and cellular therapy.Treating breast cancer with cell-based approaches: an overview.Elevated T cell activation score is associated with improved survival of breast cancer.Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer.A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens.Socializing Individualized T-Cell Cancer Immunotherapy.The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy.Improving radiotherapy in cancer treatment: Promises and challenges.Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry.'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.Unbiased Identification of T-Cell Receptors Targeting Immunodominant Peptide-MHC Complexes for T-Cell Receptor Immunotherapy.Universal Patterns of Selection in Cancer and Somatic Tissues.Neoantigen prediction and the need for validation.CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients.Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma.A library-based screening method identifies neoantigen-reactive T cells in peripheral blood prior to relapse of ovarian cancer.An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes.The role of mass spectrometry and proteogenomics in the advancement of HLA epitope prediction.Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes.Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?Hitting the Target: How T Cells Detect and Eliminate Tumors.Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.Effects of thymic selection on T cell recognition of foreign and tumor antigenic peptides.Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses.Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma.CD63-Mediated Antigen Delivery into Extracellular Vesicles via DNA Vaccination Results in Robust CD8+ T Cell Responses.Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells.
P2860
Q28080312-09C18367-9A62-4D98-A373-3024D3E8CE2DQ31148562-A3F75948-24E9-4CFF-83FC-AFE177E7607CQ33806351-DB39F610-27F4-4F5A-B845-D781A0C0F709Q37349280-B4B4FB2B-4A4D-4465-87D0-669BF39554BAQ37742635-3E278502-D0D2-42E0-A9B2-6BC485AA370CQ38767662-5A7CCA32-8E7F-44F1-8488-3C7FAC50D9CFQ39057617-24E42593-3C65-4506-9E6E-EB30902C3F1CQ39067933-184152DF-8EED-4CA8-AE03-835F2DD10A82Q39084427-B354075A-46D0-48F7-A614-9D848FAFF140Q39149196-B7377599-F7FE-4418-A0A7-2AF407314BE7Q39178061-48644C32-24D4-41BC-9E58-CEC2D39FDEC7Q39216720-D267346F-8C75-411F-BA62-6F9A75D94F78Q39448180-C02BE667-CB5B-437D-B46A-78ABD1474281Q40208127-52516F71-8B43-46A8-A3C8-885318E4C705Q40242985-E9973B03-3F72-4798-B0EB-C12556C875FFQ41279621-A06E8383-1160-496C-82C9-314B7A46B33DQ41635793-0D71498D-5349-4F56-BDD9-EB16680E1F63Q41673084-67CF78DE-7BCA-4091-A00F-1923397EB5F7Q41899048-2279E5F5-9162-480A-8AB4-7C3C70EFD4ADQ42143897-9DBED23C-6E15-4EAB-AC37-730316D14D9FQ45718710-5938ED2B-4DB0-4C5A-A300-9AE8B48B1789Q45872498-A23D6065-8283-4801-85C2-0D493D3597E4Q46278243-ED132FCD-29D8-4294-AFA1-FDCAE674A5DCQ46969749-D3AFD1D7-C59A-47A9-AE05-F6A2E13B0E76Q47122613-6F0683AA-F098-4CBA-A8EA-869086442287Q47133741-275D05B1-8FCE-4396-BA2F-713CE3978BACQ47153393-FC75BF18-D6F1-41B5-80A2-540FE3E6BF01Q47157821-26A70FAF-BEE3-4217-B630-3DD5753C7B25Q47162995-BB8D9DF7-FAF2-4F7E-A4DB-BA39C36EFB24Q47190955-28EF421E-3F63-47D9-A896-A65AC8389EEDQ47220965-5A3B2CA8-6A2C-4FAD-B315-7CFEA5C0B69DQ47221163-AAA355B8-E0D1-4227-A416-BFDB9F8C2583Q47222791-0A51F166-8E69-4DC7-B135-BA46A7BFFBDAQ47394131-4D36938C-EB45-4475-832F-D8F117647941Q47569621-D7A8E253-CBFE-4189-A1BE-F12EFAC6A6E6Q47621538-4CCFD991-870D-4B42-BBC6-9B938BAE848CQ47835567-CFABE574-6714-415E-A0B0-B646047CB882Q47947510-FBA3F47C-633C-40C4-822D-D352D0CB6605Q48142387-223DE23B-52A8-455E-A928-59DCD8A0012FQ48243270-17DE2638-C38B-4854-8542-63660CB1ABF8
P2860
Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.
@ast
Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.
@en
Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.
@nl
type
label
Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.
@ast
Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.
@en
Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.
@nl
prefLabel
Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.
@ast
Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.
@en
Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.
@nl
P2093
P2860
P50
P356
P1433
P1476
Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.
@en
P2093
Erlend Strønen
Johanna Olweus
Marit M van Buuren
Maxi-Lu Böschen
Mireille Toebes
Nienke van Rooij
Sander Kelderman
Weiwen Yang
P2860
P304
P356
10.1126/SCIENCE.AAF2288
P407
P577
2016-05-19T00:00:00Z